Cheng-Han Lee


Dr. Lee received his MD-PhD degree and pathology residency training from the University of British Columbia. He completed a year of post-doctoral research fellowship studying ovarian and uterine cancer at Stanford University as well as a year of cancer genetics and biology research on gynecologic cancer at Brigham and Women's Hospital in Boston. His work on uterine cancer led to the recognition of a new cancer type that was adopted in the WHO classification system. The focus of his research over the past decade has been on the genetics and biology of aggressive gynecologic cancer, and he has applied various next generation sequencing methods and high-throughput assays to gain novel insights into these tumors, including the most aggressive subtypes of uterine cancer such as dedifferentiated endometrial cancer and carcinosarcoma. Dr. Lee currently has over 140 publications including chapters from the latest WHO classification of female genital tumors. Dr. Lee is currently be a staff and consultant pathologist with a diagnostic focus on gynecologic cancer at Royal Alexandra Hospital and his research team is be based at University of Alberta campus.

Stories this researcher is featured in:

June 24, 2022

Accelerating precision health for ovarian cancers

A pathologist recreates disease in a petri dish to tailor cancer treatments

Featuring Cheng-Han Lee Read more
June 24, 2021

Women’s Health Research Spotlight: Cheng-Han Lee

Cheng-Han Lee has spent the last decade examining the genetic basis and biology of aggressive gynecologic cancer. As the newly appointed Sawin-Baldwin Chair in Ovarian Cancer, Lee will focus on gynecologic cancers that are most aggressive and most in need of therapeutic advancement.

Featuring Cheng-Han Lee Read more